Thursday, 4 June 2020

Medical Drones Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2025

Market Forecast
Medical Drones’ Market is expected to worth USD 398 Million by 2025 and is anticipated to register a CAGR of 24.4% during the forecast period (2019 to2025).
Market Synopsis
Medical drones help in the transport of medical supplies such as vaccines, medications, and medical aids. These drones are deployed in remote or inaccessible areas for the rapid & secure distribution of medical supplies and the war-torn regions from medical facilities. Rising public acceptance of medical drone is also driving the growth in medical drones market demand.
Medical Drones Market Size, In recent years, has been seeking the attention of healthcare providers and governments to offer better healthcare services to remote locations. These drones help in on-time delivery of vaccines, medication, blood, and supplies to the origin and thereby reduce the outbreaks of life-threatening infectious diseases.
How can this technology help in improving safety and care delivery?
  • Bedside medication delivery
  • Effective treatment from the distance
  • Easy reach to an isolated place
  • Pre-treatment facility till the time emergency service arrives at takeover
Most of the key players in the market are focusing on developing medical drones to deliver medical supplies to far distances. For instance, in 2016, a Nevada based start-up Flirtey delivered medical test materials and supplies to and from an offshore vessel. This was the first successful ship to shore delivery in the U.S.
Market Influencer
Increasing investments by key players in R&D is the key factor driving the growth of the Global Medical Drones’ Market.
Market Drivers
  • Rising participation of Governments in various countries: Active involvement of local governments towards the deployment of drone service to remote and isolated areas is boosting the growth of the market. For instance, in 2018, the government of Ghana has signed an agreement with Zipline (US) for the deployment of drones throughout the country to provide medical supplies to untapped regions
  • Increasing application of drone for the supply of medical products such as blood, pharmaceuticals/drugs, and vaccines are anticipated to propel the market growth during the forecast period
  • Technological advancements to improving the accuracy of medical drones during emergency cases backed by R&D activities by key players
Market Restraints
  • Medical drones. Medical drones are not allowed to fly without the permission of the government. Thus, product approval laws are expected to restrict the growth of the medical drone’s market during the forecast period.
Segmentation
By Application
  • Blood Transfer: Rising incidence of severe bleeding deaths is boosting the demand for medical drones. The blood transfer segment is anticipated to show a growth rate of ~24% during the analysis period. According to the MRFR analysis, each year, around 60,000 Americans die from blood loss or hemorrhaging. Moreover, around 2 million people die across the globe.
  • Pharmaceutical/Drugs Transfer: The increasing focus of key medical drones vendors towards the development of drones for medication delivery is boosting the growth of this segment.
  • Vaccines Transfer: This segment is mainly on the drones that are associated with the delivery of the vaccine.
By End-User
  • Emergency Medical Services: This segment held the largest market share in 2018, owing to continues advancements in technology. For instance, in 2019, an automated drone’s delivery company Zipline (US), has planned for the expansion of a medical drone network into Ghana for emergency services.
  • Blood Banks: Owing to poor road conditions, transporting blood in underdeveloped countries is a huge task. Medical drones carry blood, plasma, and platelets from blood banks to remote hospitals and clinics.
By Region
  • Americas: The Americas held the largest regional market in 2018, owing to rising technology advancement. Moreover, the governments in this region are also promoting the acceptance of medical drones, as a result, players are aggressively working to develop advanced drones. In October 2019, United Parcel Services (US) received an authority from the Federal Aviation Administration to deliver medical packages at hospitals across the country.
  • Europe: The European market is expected to be the second-largest market in 2025. The market growth in this region can be attributed to government funding and support to the healthcare sector, coupled with increasing research and development.
  • Asia-Pacific: Asia-Pacific is the fastest-growing region for the medical drones market owing to the improving healthcare infrastructure, rising investments in healthcare, and expansions by market players in the region. Also, countries such as India and China are expected to be the fastest-growing in the region due to the focus of governments towards the adoption of new technologies and faster adoption of best treatment options from developed countries.
  • Middle East & Africa: It is projected to account for the least share of the global market due to an underdeveloped healthcare sector.
Key Players
  • DJI (China)
  • DHL (Germany)
  • Embention (Spain)
  • Flirtey (US)
  • Matternet (US)
  • Vayu (US)
  • Zipline (US)
  • EHang (China)
  • TUDelft (Netherlands)
Posted by at No comments:

Global Thalassemia Treatment Market Trend, Industry Overview, Competitive Analysis And Foreseen By 2025

Market Forecast
Thalassemia Treatment Market Size is expected to cross USD 3763 Million by 2025 at a CAGR of 10.4%.
Thalassemia, specifically the Beta- thalassemia disorder, is majorly caused by the mutation in the Hemoglobin Subunit Beta (HBB) gene. For instance, at least 5.2% of the world population and over 7% of pregnant women have a genetic mutation.
Market Synopsis
Thalassemia Treatment Market analysis asserts that, Thalassemia is an inherited blood disorder wherein the body makes an inadequate amount of hemoglobin. Hemoglobin disorders were initially prevalent in 60% of 229 countries, that potentially affected 75% of births, but are now sufficiently common in 71% of countries amongst 89% of births.
Market Influencers
Major companies are concentrating on mergers and acquisitions, new product developments, approvals, and regional expansions. For instance, in September 2019, Bluebird Bio, Inc. (US) has approved the first gene therapy for Beta-thalassemia. This gene therapy eliminates the need for blood transfusions in patients with β-thalassemia. Thus, major manufacturers are focusing on approvals in thalassemia treatment, which ultimately drives the growth of the market.
Market Drivers
  • The rising incidence of thalassemia is expected to drive the growth of the market. Patients with insufficient hemoglobin suffer from thalassemia. For instance, thalassemia affects approximately 4.4 of every 10,000 live births throughout the world.
  • Increasing pipeline drugs in thalassemia is expected to drive the growth of the market. There are approximately 15 pipeline products under clinical trials for the treatment of thalassemia. For instance, in December 2016, Kiadis Pharma announced initiation of Phase I/II clinical trial with ATIR201 for thalassemia.
  • A rise in awareness regarding available treatment options for the treatment of thalassemia is expected to drive the growth of the market.
  • The rise in demand for improved curative gene therapy is expected to drive the growth of the market.
Market Restraints
  • Stringent regulatory policies
  • High treatment costs
Segmentation
By Type
  • Alpha-thalassemia: Fastest growing segment. It is one of the most common autosomal recessive disorders. There is an increased incidence of the alpha-globin disorders in the US and other Western nations which eventually drives the growth of the thalassemia treatment market. However, about 5% of the world’s population is affected by alpha-thalassemia.
  • Beta Thalassemia: It is caused by reduced or no production of beta-globin subunits. About 1.5% of the global population is affected by Beta-thalassemia.
By Treatment
  • Blood Transfusions: The largest growing segment owing to the low risks involved due to careful blood screening. This treatment gives strong red blood cells along with normal hemoglobin. About 56,000 population have major thalassemia, wherein, at least 30,000 need regular blood transfusions. Thus, rising demand for blood transfusions is expected to drive the growth of the market.
  • Iron Chelation Therapy: This includes removing excess iron from the bloodstream. Iron chelator drugs such as desferrioxamine, deferiprone, and deferasirox are majorly used in this treatment.
  • Folic Acid Supplements: Folic acid is vitamin B that helps build strong red blood cells. These supplements are majorly consumed during and after pregnancy. However, 4% had started consuming after becoming pregnant. Thus, the increased use of folic acid is expected to drive the growth of this segment.
  • Gene therapy: Scientists are investigating genetic techniques to treat thalassemia. Gene therapy named Zynteglo was first launched by Bluebird Bio, Inc. (US) in September 2019.
  • Bone Marrow transplants: These transplants are not done very often as significant risks are involved but can be tried if no bone marrow matched donor is available. However, the patient will not need further blood transfusions if this transplantation is done. As a result, it would drive the market growth in this segment.
By End-User
  • Hospitals & Clinics: Holds the largest market share owing to the increase in the number of hospital admissions for the treatment of thalassemia. Moreover, increasing occurrence of thalassemia is also expected to drive this segment.
  • Diagnostic laboratories: This segment holds significant market share owing to the increasing awareness regarding thalassemia treatment.
  • Others: This segment includes research laboratories, educational institutes, among others.
By Region
  • Americas: The largest growing regional market owing to rising awareness about thalassemia and increasing government efforts to support gene therapy. However, Beta-thalassemia disorder is relatively rare in the US.
  • Europe: The introduction of gene therapy for the treatment of thalassemia is expected to boost the growth of market. For instance, in September 2019, Bluebird Bio, Inc. (US) has obtained approval for gene therapy that would remove the need for blood transfusions for people with blood disorder beta-thalassemia.
  • Asia-Pacific: The fastest-growing regional market in thalassemia treatment. Increasing investment in healthcare infrastructure is expected to drive the growth of the market in this region.
  • Middle East & Africa: Increasing adoption rate of blood transfusion treatment in countries such as Turkey and GCC would drive the demand for thalassemia treatment in this region.
Key Players
  • Novartis AG (Switzerland)
  • Bluebird Bio, Inc. (US)
  • Kiadis Pharma (Netherlands)
  • CELGENE CORPORATION (US)
  • Sangamo Therapeutics (US)
  • Acceleron Pharma, Inc. (US)
  • Gamida Cell (Israel)
Posted by at No comments:

Cardiac Biomarkers Market Size Estimation By Top Manufacturer, Latest Trends And Global Industry Forecast 2019 To 2025

Market Forecast
Cardiac Biomarkers Market Size is expected to cross USD 4236.02 Million by 2025 at a CAGR of 16.36%.
Cardiac biomarkers are protein molecules released into the bloodstream from heart muscle damaged by a blocked artery. These enzymes are measured to have an idea of how much muscle damage has been done. These biomarkers are specially used to help diagnosis, evaluate, and monitor patients with suspected acute coronary syndrome (ACS).
The increasing prevalence of cardiovascular diseases is expected to drive the growth of the global Cardiac Biomarkers Diagnostics Market Trends. Out of the 17 million premature deaths due to noncommunicable diseases in 2015, 82% were in low- and middle-income countries, and 37% were caused by cardiovascular diseases.
Market Synopsis
Tests for cardiac biomarkers are used to diagnose acute coronary syndrome (ACS) and cardiac ischemia, conditions associated with insufficient blood flow to the heart. These biomarkers are also helpful in determining a person's risk of these conditions and also helps monitor and manage someone with ACS and cardiac ischemia.
Troponin T and I, CK-MB, and myoglobins are most commonly in the evaluation of acute coronary syndrome. Out of this troponin T and I are the markers of choice for detecting the heart damage. However, other cardiac biomarkers are less specific for heart and may be elevated in other conditions like severe muscle injury, liver disease, and kidney disease.
The increasing incidence of cardiac diseases and related conditions are strongly motivating market players to introduce new efficient technologies in the market.
Market Influencers
High prevalence of cardiac disorders and increasing participation of market players are actively facilitating the growth of the cardiac biomarkers market. In September 2019, Abbott received FDA clearance for ARCHITECT STAT High Sensitivity Troponin-I blood test. This troponin diagnostic test will be used to detect heart attacks faster and more accurately than contemporary troponin tests.
Market Drivers
  • High prevalence of raised blood pressure: Raised blood pressure is the leading risk factor for cardiovascular disease. The prevalence of this troponin T blood pressure in adults aged 18 years and over was around 24.1% in men and 20.1% in women in 2015
  • Increasing adoption of outsourcing services
  • Growing technological advancements:
  • High spending by the pharmaceutical industry
  • The increasing popularity of POC cardiac testing kits
  • Increasing affordability for advanced cardiac treatments
Market Restraints
  • Chances of false diagnosis of myocardial infarction
  • High cost of the procedure
  • Presence of other efficient methods for the diagnosis of cardiovascular diseases
Cardiac Biomarkers Market Segmentation
By Type
  • Myocardial muscle Creatine Kinase (CK-MB): CK-MB has been the gold standard for detecting myocardial necrosis. After myocardial infarction, elevated CK-MB levels appear within 3- 8 hours, peaking within 9-30 hours and levels return to normal after 48- 72 hours
  • Troponins (T and I): The most important characteristic of this biomarker is its apparent absolute cardiac specificity. Among patients with acute coronary syndromes, troponins level has been reported to provide prognostic information useful for the early identification of patients with an elevated risk of unstable angina progressing to AMI and death
  • Myoglobin: Myoglobin is a low molecular weight heme protein is rapidly released into the circulation and is the first marker to exhibit raising levels after myocardial infarction
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP: This biomarker is secreted primarily by the ventricular myocardium in response to wall stress. It is a very useful prognostic indicator in acute coronary syndrome
  • Ischemia Modified Albumin (IMA): This novel marker is produced when circulating serum albumin contacts ischemic heart tissues. IMA can be measured by the Albumin Cobalt Binding assay that is based on IMA's ability to bind to cobalt.
By Location of Testing
  • Point of Care Testing: Point of care testing expected to witness significant growth in the forecast period due to its increasing popularity
  • Laboratory Testing: Laboratory testing segment dominated the global cardiac biomarkers market. Increasing demand for cardiovascular disease diagnostics is boosting the revenue of this segment
By Application
  • Acute Coronary Syndrome: This segment holds the largest share owing to the increasing cases of this condition. It is a medical emergency that requires prompt diagnosis and care.
  • Congestive Heart Failure: It is a chronic progressive condition that affects the pumping power of your heart muscles
  • Myocardial Infarction: Approximately 1.5 million cases of myocardial infarction occur annually in the US region.
  • Atherosclerosis: Atherosclerosis is a disease in which plaque builds up inside your arteries. Cardiac troponins are used to assess the prognosis of patients presenting with atherosclerosis
By Region
  • Americas: The largest regional market. High prevalence of cardiac diseases is strongly expanding the US cardiac biomarkers market. As per the data suggested by the Centers for Disease Control and Prevention (CDC), around 610,000 people die of heart disease in the US every year. Also, coronary heart disease (CHD) is the most common type of heart disease, killing over 370,000 people annually.
  • Europe: Europe has some of the best healthcare services in the world, and rising participation of market players is strongly boosting the Europe cardiac biomarkers market. For instance, in October 2019, Novartis received FDA approval for Entresto for the treatment of symptomatic heart failure in pediatric patients aged one year and older.
  • Asia-Pacific: The fastest-growing regional market for Cardiac Biomarkers, Asia-Pacific, has the world’s largest population and fast-developing healthcare industry. Rising affordability for the advanced cardiac treatments and increasing disposable incomes are strongly impacting the growth of the Cardiac Biomarkers market in the region
  • Middle East & Africa: The Middle East & Africa has been primarily bifurcated into two regions—the Middle East and Africa. The presence of favorable government initiatives and recent healthcare reforms and developing healthcare infrastructure in the Middle East is expected to augment the market growth over the forecast period.
Key Players
  • Abbott Laboratories (US)
  • ACS Biomarker (The Netherlands)
  • BD (Becton, Dickinson and Company) (US)
  • bioMérieux SA (France)
  • Bio-Rad Laboratories, Inc. (US)
  • Danaher Corporation (US)
  • Hoffmann-La Roche Ltd (Switzerland)
  • Johnson and Johnson (US)
  • Quidel Corporation (US)
  • Randox Laboratories Limited (UK)
  • Siemens AG (Germany)
  • Thermo Fisher Scientific, Inc. (US)
  • Trivitron Healthcare Pvt. Ltd. (India)
  • Novartis (Switzerland)
Posted by at No comments:

STD Testing Devices Market Worldwide Key Players Forecasts By Revenue, Growth Rate Till 2025

Market Forecast
STD Testing Devices Industry Market Growth Share accounted for USD 70.29 Billion in 2018 and is expected to register a CAGR of 9.3% during the forecast period.
Market Synopsis
Sexually transmitted disease (STDs) is an infection caused due to some organisms. STDs can be transmitted from one person to another through sexual activity and intimate contact. The cases of sexually transmitted diseases keep climbing among 45 and older Americans. 82,938 cases of gonorrhea, syphilis, and chlamydia were reported among 45 and older Americans in the year 2016.
Market Influencer
The increasing prevalence of lifestyle diseases, rising geriatric population along with increasing awareness about sex-related diseases is influencing the market growth positively. The increasing number of product launches by key players in the market are likely to act as a promising factor for the increase in the near future.  For Instance, Quest Diagnostics launched three new sexually transmitted disease (STD) laboratory test packages that individuals can purchase online for some of the most prevalent STDs in the United States.
Market Drivers
  • Increase in prevalence of sex-related diseases
    • Every year, 376 million new cases of chlamydia, syphilis, gonorrhea, and trichomoniasis are reported globally. The total estimated direct cost of STIs annually in the U.S. is about USD 16 billion.
    • The most common STIs affecting a lot of people are Chlamydia, gonorrhea, and syphilis. Approximately 1.5 million cases of chlamydia were reported in 2015 in US alone which represents it to be the highest number of annual cases of any condition ever reported.
    • A total of 89,239 cases of gonorrhea were reported by 27 states of the European Union in 2017.
  • Increasing prevalence of lifestyle diseases
  • Rise in healthcare expenditure
  • Increasing geriatric population
  • Increasing mergers & acquisitions by prominent players in the market
    • For instance, in 2019, the US Food and Drug Administration (FDA) has cleared two tests "The Aptima Combo 2 Assay (Hologic Inc) and the Xpert CT/NG (Cepheid)" to detect Chlamydia trachomatis and Neisseria gonorrhoeae from throat and rectum samples.
  • Increasing awareness about STIs
Market Restraints
  • Lack of information about the symptoms and causes is hampering the growth of the market.
Segmentation
By Type
  • Laboratory Devices: It is expected to hold a larger share. Laboratory devices are the traditional methods of detecting STI and a large number of hospitals and clinics are expected to be using the laboratory devices.
  • Point of Care (POC) Devices: It is expected to be the fastest-growing segment as it is less time-consuming.
By End-User
  • Hospitals and Clinics: Hospitals and clinics segment dominates the global market for The positive growth of hospitals is attributed to factors such as high volume of STD tests performed in hospital-based laboratories across the globe and growing patient population.
  • Diagnostic Laboratories: Diagnostic Laboratories segment take up the second-largest share due to the rising number of diagnostic labs and the increasing patient population.
  • Research Laboratories and Institutes: segment is projected to be the fastest-growing segment over the assessment period. The research and development activities with respect to STD diagnostics and treatment have increased in last decade which has resulted in the growing demand for the devices and kits in the R&D facilities. Besides that, government funding for the research and development for effective treatment of STD has pushed the growth of this segment. The researchers from King's College London, have published a study in Nature Communications, according to them skin vaccination can generate protective CD8 T-cells that are recruited to the genital tissues and could be used as a vaccination strategy for sexually transmitted infections (STIs).
By Region
  • Americas: It is the largest regional market owing to the factors such as large patient population, rise in prevalence of STIs, the availability of a wide variety of STD testing kits and surges in awareness about the causes of STIs and its treatments which are driving the growth of the market in this region.
    • According to the Centers for Disease Control and Prevention (CDC), more than 1300 cases of congenital syphilis, about 40% increase was reported in newborns during 2017-2018 in US. Similarly, a rise in 8487 new cases of women suffering from gonorrhea in US alone was reported during the year 2017-2018.
  • Europe: The key factors driving the market growth are the growing research and development support by government bodies for the healthcare sector, and the significant demand for STI testing is driving the growth of the STI testing devices market in Europe. Additionally, the rising initiatives by organizations are driving market growth. For Instance, EuroTEST initiative is a platform for information exchange and activities to improve early diagnosis and care of HIV, viral hepatitis, sexually transmitted infections, and tuberculosis.
  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global STI testing devices market. The rising patient population is driving the growth of the Asia-Pacific STI testing devices market. Additionally, increasing disposable income of the middle-class population, and improving healthcare infrastructure in emerging countries such as China and India are driving the market growth. However, unfavorable healthcare reforms may restrain the growth of the market to some extent.
  • Middle East & Africa: This region is the smallest market due to limited healthcare infrastructure and limited exposure to technological advancements.
Key Players
  • Abbott (US)
  • MedMira Inc. (Canada)
  • Qaigen Inc. (US)
  • Thermo Fisher Scientific (US)
  • Cepheid (Danaher Corporation) (US)
  • Hoffmann-La Roche AG (Switzerland)
  • Diasorin S.p.A (Italy)
  • Bio-Rad Laboratories, Inc. (US)
  • bioMeriuex (France)
  • Becton Dickinson and Company (US)
  • Hologic, Inc. (US)
  • GenePOC Inc. (Canada)
  • Meridian Bioscience (US)
  • OraSure Technologies (USTop of FormBottom of Form
Posted by at No comments:

Healthcare Personal Protection Equipment Market Expects An Extensive Growth In Roi Till 2025

Market Forecast
Registering a CAGR of 9.17%, the Global Healthcare Personal Protection Equipment Market is expected to reach USD 10.116 Billion by 2027.  
As the Coronavirus (COVID-19) virus continues to spread across the world, many healthcare companies such as 3M and DuPont are focused on increasing the production of personal protective equipment and other medical supplies to help with prevention and control of global pandemic. For instance, in April 2020, DuPont, US-based healthcare company, launched a new program, TyvekTogether, to increase the overall availability of Tyvek personal protective garments to help combat the spread of COVID-19 and protect health care workers.
Regional Analysis
On a regional basis, the Americas is anticipated to dominate the global healthcare personal protection equipment market owing to the presence of a favorable regulatory scenario to increase the safety and security of healthcare professional. Additionally, the US Food and Drug Administration (FDA) is collaborating with manufacturers of personal protective equipment (PPE) to help facilitate mitigation strategies related to the COVID-19 outbreak. Europe is expected to hold the second-largest position in the global healthcare personal protection equipment market owing to the presence of a robust healthcare infrastructure and well-established market players. Furthermore, the rapid spread of COVID-19 pandemic in Italy, France, Spain, the UK, Germany, and other countries is increasing the adoption of personal protective equipment.
Asia-Pacific is anticipated to be the fastest-growing region is due to the rising demand of PPEs on the account of COVID-19 outbreak, technological advancements, favorable regulatory scenario, and the rising importance of safety & security among the healthcare industry. The growth of the Middle East & Africa is attributed to the technological development in the field of medical and healthcare industry, high penetration of PPEs in developed healthcare economies such as Saudi Arabia and UAE.
Segmentation
The global healthcare personal protection equipment market has been segmented into product and end-use.
By product, the market has been segregated into protective clothing, respiratory protection, head, eye and face protection, protective footwear, hand protection, and others. The protective clothing is further segmented into coveralls, gowns, and others. Respiratory protection is bifurcated into surgical masks, respirator masks, and others. Hand protection is further sub-segmented into general-purpose, chemical handling, sterile gloves, and surgical. The respiratory segment is expected to witness the highest CAGR during the forecast period owing to the rising demand for surgical masks and respirators for protecting the hospital staff against pathogens and contaminants.
On the basis of end-use, the global healthcare personal protection equipment market has been classified as hospitals & clinics, ambulatory surgical centers, academic & research institutes, diagnostic laboratories, and others. The hospitals & clinics segment is expected to hold the largest market share owing to the rising number of people opting for medical services for treatment coupled with an increasing number of physicians in the emerging economies.
Key Players3M (US), Honeywell International Inc. (US), Medtronic PLC (Ireland), Ansell (Australia), Sterimed (US), DuPont (US), Crosstex International, Inc. (US), Medisca Inc. (US), Alpha Pro Tech (Canada), Plasti Surge Industries Pvt. (India), Kimberly-Clark Worldwide, Inc. (US), Halyard Health, priMED Medical Products, Inc. (Canada), Med-Con (Australia), KOWA (Japan)
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/healthcare-personal-protection-equipment-market-9594 
Posted by at No comments:

Particle Counter Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2025

Market Forecast

Global Particle Counter Market size is expected to cross USD 168.2 Million by 2025 at a CAGR of 7.1% during the forecast period of 2019 to 2025.
Market Synopsis
A particle counter is a tool for monitoring indoor air quality to understand the concentration of particles in the air in cleanrooms and workplaces. This device would not identify specifically what kinds of dust particulates are present in the air, but it will identify how many airborne particles of a certain size are present in the environment.
The growing pharmaceutical sector along with stringent regulatory policies are driving the particle counter market growth. Additionally, increasing numbers of growth strategies adopted by major players are further driving the market growth globally. For instance, in June 2019, TSI launched the AeroTrak+ Remote Airborne Particle Counters for monitoring manufacturing cleanrooms.
Market Influencer
Rising production by the pharmaceutical industry and stringent regulations are likely to impact the growth of the particle counter industry positively.
Market Drivers
  • The growing pharmaceutical industry will support the growth of the particle counter market during the forecast period.
  • Rising research & development in the pharmaceutical and biotechnology industry to cater to rising needs for treatments of various chronic diseases is driving the growth of the particle counter market. For instance, according to a recent survey, the pharmaceutical and biotechnology industry in the US spent a total of USD 102 billion on research & development in 2015. Additionally, according to the National Institute for Health Research, the Association of the British Pharmaceutical Industry (ABPI) invested over USD 4.46 billion just in the UK on R&D, looking for breakthroughs for conditions such as cancer, dementia, and rare genetic diseases.
  • Stringent government regulations regarding the quality of air in the pharmaceutical and medical device industry.
  • Rising product launches and product advancements by major market players.
Market Restraints
  • The high cost of particle counters and technical limitations of particle counters is hampering the growth of the global particle counter market.
Particle Counter Market Segmentation
By Product Type
  • Airborne Particle Counters: Airborne particle counters are widely used to monitor signs of cleanroom air contamination, and, in most cases, the particle count data is used to make critical process decisions regarding cleanroom certifications. These airborne particle counters, work on a light scattering principle. They utilize a very bright light source to illuminate the particles.
  • Liquid Particle Counters: Liquid particle counting is used to measure the size and distribution of particles in a liquid or on solid samples. This particle counter works by irradiating a liquid sample with a laser diode and detecting the scattered light. The properties of the scattered light are related to the particle size. The particle size is then measured, and the number of particles present in each size range is determined. Aviation & space exploration, heavy machinery, and automobile manufacturing are the fields where particle control in hydraulic systems plays an important role.
By Technology
  • Online Particle Counters: Online/Inline measuring systems are designed to mount directly to stationary systems for continuous or periodic monitoring or can be used as mobile monitoring solutions in hydraulic and lubricating systems.
  • Offline Particle Counters: Offline particle counters use mineral as the operating fluid, and their portable size makes them most suitable for on-site applications. These particle counters are widely used for automatically measuring & displaying particulate contamination, moisture & temperature levels in various hydraulic fluids.
By Modularity
  • Portable Particle Counters: The portable particle counter holds the majority share in the modularity segment attributing to the high adoption rate of these systems across the globe. Portable particle counters are easy to handle and are designed to save time and money. Demand for portable particle counters is rapidly growing in aerospace, automotive, pharmaceutical, oil & gas, and food & beverage industries.
  • Remote Particle Counters: Remote Particle counters are perfect for monitoring large cleanrooms or critical environments. Their small size, flexible power options, and wireless capabilities make them a preferred option for large clean rooms.
  • Handheld Particle Counters: These particle counters being lightweight and easy to carry, well-suited for cost-effective spot-checking. They are ideal for checking sources of contamination and perform indoor air quality (IAQ) investigations for consistently meeting the air quality parameters.
By End-User
  • Medical Device Industry: In 2018, the medical device industry held the largest share in the market due to increased R&D expenditure and the establishment of new manufacturing facilities by global pharmaceutical giants in newer geographies. Additionally, increasing infections arising due to contaminated devices and the implementation of stringent regulations to maintain air quality is driving the market growth.
  • Pharmaceutical Industry: Pharmaceutical industry accounted for the second-largest market share due to the growing volume of compounds to be detected for the presence of impurities in pharmaceutical samples and stringent safety regulations. Effective sterilization processes are vital within the pharmaceutical industries, and the safety of process units and final products depends on the highest quality of hygienic practice, as well as strict controls and regulatory compliance. Air quality rules and regulations need to be complied to ensure that the product remains sterile. This leads to a rise in the particle counter market as pharmaceutical firms are emphasizing on the use of particle counter methods to ensure air quality.
  • Research Laboratories: Particle countering is a key factor of air quality monitoring in laboratories where products or processes are sensitive to environmental contamination.
  • Others: Others include hospitals, specialty centers, diagnostic centers.
By Region
  • Americas: The Americas held the largest regional market share in 2018. This is owing to the high adoption rate of particle counters and stringent regulations by the FDA. Additionally, product launches and product advancements by major market players are driving the growth in the Americas region.
For instance, in February 2018, Particle Plus launched Particles Plus 2000 series in four size channels—0.3, 0.5, 1.0, and 5.0 µm.
  • Europe: The need for particle counter is high in this region due to growth in the pharmaceutical and medical device industry. Additionally, increasing support from governments, the presence of a huge geriatric population, and rising healthcare spending are driving the market growth.
  • Asia-Pacific: The Asia-Pacific region accounted for the third-largest market share due to presence of a large number of research organizations, low manufacturing cost and labor cost, developing healthcare infrastructure, and increased investments by the American and European market giants in Asian countries such as China and India
  • Middle East & Africa: It is estimated to account for the least share of the global particle counter market due to the limited development of healthcare facilities.
Particle Counter Market Key Players
Particle Measuring Systems, Inc. (A Spectris Company), Beckman Coulter (A Danaher Corporation Company), Rion Co., Ltd., Lighthouse Worldwide Solutions, Inc., TSI Incorporated, Climet Instruments Company, Setra Systems, Met One Instruments, Inc., Chemtrac, Inc.
Posted by at No comments:

Global Whole Exome Sequencing Market Set For Big Growth - Foresight By 2025

Market Overview

Global Whole Exome Sequencing Market size is expected to register a CAGR of 19.80% to reach USD 2,696.03 Million by 2025.
Synopsis
Whole exome sequencing is a widely used next-generation sequencing (NGS) method to determine the nucleotide sequence primarily of the protein-coding regions of an individuals related sequences, representing approximately 1% of the complete DNA sequence. The human exome represents less than 2% of the genome but contains ~85% of known disease-related variants. This is the key reason for the usage of exome in the identification and the determination of genetic variants causing various diseases such as Miller syndrome and Alzheimer’s.
Factors that drive the market growth are the decreasing cost of sequencing, the use of whole-exome sequencing technology for varied applications, and strategic alliances amongst key players & research institutes. However, the lack of skilled professionals and ethical & legal issues related to whole-exome sequencing are hampering the growth of the market.
Market Dynamics
Market players operating in the global whole exome sequencing market are focusing on product launches, approvals, and partnerships to gain market dominance and keep their product updated and in demand. For instance, in November 2019, NantHealth, Inc. (US), a next-generation, personalized healthcare company, received FDA authorization of Omics CoreSM, the first whole-exome sequencer used to analyze both tumor and somatic gene to measure overall tumor mutational burden (TMB) in cancer tissue.
Segmentation
Global Whole Exome Sequencing Market has been segmented on the basis of Product, Technology, Application, and End User. The market, based on product, has been segmented into kits, sequencer, and services. Kits are further segmented into DNA Fragmentation, End Repair, A-Tailing, And Size Selection Kits, Library Preparation, and Target Enrichment. Services are further sub-segmented into Sequencing Services, Data Analysis (Bioinformatics), and Others. The global whole exome sequencing market, by technology, has been categorized as Sequencing by Synthesis (SBS), ION Semiconductor Sequencing, and others. The market by application is segmented into diagnostics, drug discovery, and development, agriculture and animal research, others. Based on end user, the market is segmented into research centers and government institutes, hospitals and diagnostics centers, pharmaceutical & biotechnology companies, and others.

Regional Analysis

The Americas was the largest market for whole exome sequencing in 2019. The growth of the Americas market is due to the high prevalence rate of cancer and other chronic disorders and rising healthcare expenditure. Additionally, favorable initiatives by the government and other organizations for the development and adoption of whole-exome sequencing technologies are driving the market for whole-exome sequencing. For instance, in 2018, All of Us Research Program, a part of the National Institutes of Health, awarded funds over USD 28.6 million to establish three genome centers in the US. These centers aim to produce genome data for researchers and the program’s precision medicine research platform, a national resource to support studies on a variety of important health questions.
Europe is the second-largest market for whole exome sequencing with Western Europe, holding the largest market share. The European market is expected to register a sturdy growth rate during the forecast period due to rising cases of cancer and increasing programs for the adoption of genome sequencing. According to the International Agency for Research on Cancer, in 2018, there were about 4,229,662 cases of cancer in Europe. This huge cases of cancer and rising genome mapping programs are expected to have a positive impact on the growth of the whole-exome sequencing market.
Asia-Pacific is expected to represent the highest market growth potential over the forecast period due to the growing patient pool and increasing technological advancements. The fast growth of the Asia-Pacific region is due to the increasing per capita income along with government initiatives to enhance the quality of healthcare. China, India, and Australia have a lucrative market for Whole Exome Sequencing due to the growing older population. Moreover, according to the report published by the United Nations in 2015, the number of older people aged 60 years or above in the world is predicted to grow by 56% between 2015 and 2030. 66% of the older population out of the total global population would also reside in the Asia-Pacific region.
In the Middle East & Africa, the whole exome sequencing market accounts for significant market share. Countries such as Kuwait, the UAE, and Saudi Arabia are likely to show steady growth due to increasing cancer cases, rising initiatives by governments to improve patient care, and favorable reimbursement policies. However, the rest of the Middle East and Africa might show an inactive growth due to affordability and accessibility issues.
Key Players
The Prominent Players in the Global Whole Exome Sequencing Market are Illumina Inc. (US), BGI (China), Eurofins Scientific (Belgium), Thermo Fisher Scientific (US), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), GENEWIZ (US), Ambry Genetics (US), Macrogen, Inc. (South Korea), Integragen SA (France), and others.
Posted by at No comments:
Subscribe to: Posts (Atom)